Epileptic
Disorders

MTLE
DRUG-RESISTANT EPILEPSY

SynapCell has a unique know-how in developping the MTLE mouse, and maintaining its performances in mirroring Human focal epilepsies. The model shows spontaneus and recurrent Hippocampal Paroxysmal Discharges (HPD), oscillatory bursts that we monitor to evaluate anti-epileptic drugs effects. As it’s non-convulsive,
none of the readouts are based on behavior analysis.

Applications: Fovcal (drug resistant) Epilepsies, Autism spectrum disorders (ASD), Alzheimer’s disease

Markers: Spikes, Hippocampal Paroxysmal Discharges (HPD)

Models: MTLE mouse (model for mesiotemporal lobe epilepsy with differential pharmacology)

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, antiepileptogenic effect, rodent model phenotyping, derisking (pro-epileptic effect)

GAERS
GENETIC ABSENCE EPILEPSY

SynapCell Worldwide exclusive licence, the GAERS rat offers several advantages for Epilepsy drug discovery and more particularly for generalized epilepsies, a mandatory step for drug development programs in epilepsy. Extremely sensitive, the GAERS shows non-convulsive, spontaneous, recurrent epileptic discharges (Spike and wave Discharges or SWD) that can be used beyond the scope of epilepsy to detect potential pro-epileptic effect of any drug.

Applications: Epilepsies, Autism spectrum disorders (ASD), Alzheimer’s disease

Markers: Spikes, Spike and wave discharge (SWD)

Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, antiepileptogenic effect, rodent model phenotyping, derisking (pro-epileptic effect)[/colR]